← All trials
NCT01761435
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2012
- Primary completion
- Jan 1, 2014
- Completion date
- Jan 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 499
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Government of SpainLead sponsor
- University of BarcelonaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- University of CantabriaOverall official - principal investigator
- HOSPITAL UNIVERSITARIO DE CRUCESOverall official - principal investigator
- COMPLEJO HOSPITALARIO REGIONAL VIRGEN MACARENAOverall official - principal investigator
- Province of Barcelona, SpainOverall official - principal investigator
- University of SevilleOverall official - principal investigator
- Spanish Network for Research in Infectious DiseasesCollaborator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.